{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T20:57:45Z","timestamp":1773262665987,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T00:00:00Z","timestamp":1583193600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p><jats:italic>Introduction<\/jats:italic> Durvalumab has been shown to confer a survival benefit after definitive chemoradiotherapy in the patients with locally advanced non-small cell lung cancer, but no studies have attempted to identify risk factors for pneumonitis after durvalumab therapy. The purpose of this study was to investigate associations between clinical and radiation dose-volume factors, and the severity of pneumonitis. <jats:italic>Methods<\/jats:italic> We retrospectively assessed the cases of 30 patients who had been started on durvalumab therapy between July 2018 and February 2019. In this study we evaluated the percentage of lung volume receiving radiation dose in excess of 20\u00a0Gy (V20) as radiation dose-volume factor. We compared V20 and some baseline factors between a grade 0 or 1 (Gr 0\/1) pneumonitis group and a grade 2 or more (\u2265Gr 2) pneumonitis group, and we performed a logistic regression analysis to establish the associations between variables and\u2009\u2265\u2009Gr 2 pneumonitis. <jats:italic>Results<\/jats:italic> Pneumonitis had developed in 22 patients (73.3%): Gr 1\/2\/3\u20135 in 8 (26.7%)\/14 (46.7%) \/0 (0%), respectively. The difference in V20 between the Gr 0\/1 group and Gr 2 group (median: 20.5% vs. 23.5%, <jats:italic>p<\/jats:italic>\u2009=\u20090.505) was not statistically significant, and thus V20 was not a risk factor for Gr 2 pneumonitis (odds ratio: 1.047, <jats:italic>p<\/jats:italic>\u2009=\u20090.303). None of the clinical factors, including sex, age, smoking history, presence of baseline pneumonitis, type of radiation therapy, location of lesion and facility, were risk factors. <jats:italic>Conclusions<\/jats:italic> Our study suggest that the severity of pneumonitis after durvalumab is unrelated to V20 or any of the clinical factors assessed in this study.<\/jats:p>","DOI":"10.1007\/s10637-020-00917-2","type":"journal-article","created":{"date-parts":[[2020,3,3]],"date-time":"2020-03-03T18:23:58Z","timestamp":1583259838000},"page":"1612-1617","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Clinical and radiation dose-volume factors related to pneumonitis after treatment with radiation and durvalumab in locally advanced non-small cell lung cancer"],"prefix":"10.1007","volume":"38","author":[{"given":"Hiroto","family":"Inoue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Ono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takanori","family":"Kawabata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuaki","family":"Mamesaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahisa","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shota","family":"Omori","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazushige","family":"Wakuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirotsugu","family":"Kenmotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tateaki","family":"Naito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruyasu","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazuaki","family":"Yasui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirofumi","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Onoe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Endo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiaki","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,3,3]]},"reference":[{"key":"917_CR1","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1172\/JCI67313","volume":"124","author":"L Deng","year":"2014","unstructured":"Deng L, Liang H, Burnette B, Beckett M, Darga T, Weichselbaum RR, Fu YX (2014) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124:687\u2013695","journal-title":"J Clin Invest"},{"key":"917_CR2","doi-asserted-by":"publisher","first-page":"e498","DOI":"10.1016\/S1470-2045(15)00007-8","volume":"16","author":"AB Sharabi","year":"2015","unstructured":"Sharabi AB, Lim M, DeWeese TL, Drake CG (2015) Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy. Lancet Oncol 16:e498\u2013e509","journal-title":"Lancet Oncol"},{"key":"917_CR3","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1016\/S1470-2045(17)30380-7","volume":"18","author":"N Shaverdian","year":"2017","unstructured":"Shaverdian N, Lisberg AE, Bornazyan K, Veruttipong D, Goldman JW, Formenti SC, Garon EB, Lee P (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18:895\u2013903","journal-title":"Lancet Oncol"},{"key":"917_CR4","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1001\/jamaoncol.2015.2756","volume":"1","author":"S Demaria","year":"2015","unstructured":"Demaria S, Golden EB, Formenti SC (2015) Role of local radiation therapy in Cancer immunotherapy. JAMA Oncol 1:1325\u20131332","journal-title":"JAMA Oncol"},{"key":"917_CR5","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1158\/2326-6066.CIR-14-0191","volume":"3","author":"R Stewart","year":"2015","unstructured":"Stewart R, Morrow M, Hammond SA, Mulgrew K, Marcus D, Poon E, Watkins A, Mullins S, Chodorge M, Andrews J, Bannister D, Dick E, Crawford N, Parmentier J, Alimzhanov M, Babcook JS, Foltz IN, Buchanan A, Bedian V, Wilkinson RW, McCourt M (2015) Identification and characterization of MEDI4736, an antagonistic anti-PD-L1 monoclonal antibody. Cancer Immunol Res 3:1052\u20131062","journal-title":"Cancer Immunol Res"},{"key":"917_CR6","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","volume":"377","author":"SJ Antonia","year":"2017","unstructured":"Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, Yokoi T, Chiappori A, Lee KH, de Wit M, Cho BC, Bourhaba M, Quantin X, Tokito T, Mekhail T, Planchard D, Kim YC, Karapetis CS, Hiret S, Ostoros G, Kubota K, Gray JE, Paz-Ares L, de Castro Carpe\u00f1o J, Wadsworth C, Melillo G, Jiang H, Huang Y, Dennis PA, \u00d6zg\u00fcro\u011flu M, PACIFIC Investigators (2017) Durvalumab after Chemoradiotherapy in stage III non-small-cell lung Cancer. N Engl J Med 377:1919\u20131929","journal-title":"N Engl J Med"},{"key":"917_CR7","doi-asserted-by":"publisher","first-page":"2342","DOI":"10.1056\/NEJMoa1809697","volume":"379","author":"SJ Antonia","year":"2018","unstructured":"Antonia SJ, Villegas A, Daniel D et al (2018) Overall survival with Durvalumab after Chemoradiotherapy in stage III NSCLC. N Engl J Med 379:2342\u20132350","journal-title":"N Engl J Med"},{"key":"917_CR8","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1016\/j.ijrobp.2012.04.043","volume":"85","author":"DA Palma","year":"2013","unstructured":"Palma DA, Senan S, Tsujino K et al (2013) Predicting radiation pneumonitis after chemoradiation therapy for lung cancer: an international individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 85:444\u2013450","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"917_CR9","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S0360-3016(99)00183-2","volume":"45","author":"MV Graham","year":"1999","unstructured":"Graham MV, Purdy JA, Emami B et al (1999) Clinical dose-volume histogram analysis for pneumonitis after 3D treatment for non-small cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phy 45:323\u2013329","journal-title":"Int J Radiat Oncol Biol Phy"},{"key":"917_CR10","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/S0360-3016(02)03807-5","volume":"55","author":"K Tsujino","year":"2003","unstructured":"Tsujino K, Hirota S, Endo M et al (2003) Predictive value of dose-volume histogram parameters for predicting radiation pneumonitis after concurrent chemoradiation for lung cancer. Int J Radiat Oncol Biol Phys 55:110\u2013115","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"917_CR11","doi-asserted-by":"publisher","first-page":"S70","DOI":"10.1016\/j.ijrobp.2009.06.091","volume":"76","author":"LB Marks","year":"2010","unstructured":"Marks LB, Bentzen SM, Deasy JO et al (2010) Radiation dose-volume effects in the lung. Int J Radiat Oncol Biol Phy 76:S70\u2013S76","journal-title":"Int J Radiat Oncol Biol Phy"},{"key":"917_CR12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.radonc.2004.02.015","volume":"71","author":"G Rodrigues","year":"2004","unstructured":"Rodrigues G, Lock M, D'Souza D, Yu E, van Dyk J (2004) Prediction of radiation pneumonitis by dose - volume histogram parameters in lung cancer--a systematic review. Radiother Oncol 71:127\u2013138","journal-title":"Radiother Oncol"},{"key":"917_CR13","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ijrobp.2005.03.047","volume":"63","author":"V Mehta","year":"2005","unstructured":"Mehta V (2005) Radiation pneumonitis and pulmonary fibrosis in non-small-cell lung cancer: pulmonary function, prediction, and prevention. Int J Radiat Oncol Biol Phys 63:5\u201324","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"917_CR14","doi-asserted-by":"publisher","first-page":"975","DOI":"10.3109\/0284186X.2012.718093","volume":"51","author":"IR Vogelius","year":"2012","unstructured":"Vogelius IR, Bentzen SM (2012) A literature-based meta-analysis of clinical risk factors for development of radiation induced pneumonitis. Acta Oncol 51:975\u2013983","journal-title":"Acta Oncol"},{"key":"917_CR15","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.semradonc.2014.12.003","volume":"25","author":"FM Kong","year":"2012","unstructured":"Kong FM, Wang S (2012) Non-dosimetric risk factors for radiation-induced lung toxicity. Semin Radiat Oncol 25:100\u2013109","journal-title":"Semin Radiat Oncol"},{"key":"917_CR16","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.radonc.2006.06.007","volume":"80","author":"I Sekine","year":"2006","unstructured":"Sekine I, Sumi M, Ito Y et al (2006) Retrospective analysis of steroid therapy for radiation-induced lung injury in lung cancer patients. Radiother Oncol 80:93\u201397","journal-title":"Radiother Oncol"},{"key":"917_CR17","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","volume":"28","author":"L Khoja","year":"2017","unstructured":"Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR (2017) Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. Ann Oncol 28:2377\u20132385","journal-title":"Ann Oncol"},{"issue":"28","key":"917_CR18","first-page":"119","volume":"suppl_4","author":"H Jbag","year":"2017","unstructured":"Jbag H, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol suppl_4(28):119\u2013142","journal-title":"Ann Oncol"},{"key":"917_CR19","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.2217\/fon-2019-0102","volume":"15","author":"T Baba","year":"2019","unstructured":"Baba T, Sakai F, Kato T et al (2019) Radiologic features of pneumonitis associated with nivolumab in non-small-cell lung cancer and malignant melanoma. Future Oncol 15:1911\u20131920","journal-title":"Future Oncol"},{"key":"917_CR20","doi-asserted-by":"publisher","first-page":"6051","DOI":"10.1158\/1078-0432.CCR-16-1320","volume":"22","author":"M Nishino","year":"2016","unstructured":"Nishino M, Ramaiya NH, Awad MM, Sholl LM, Maattala JA, Taibi M, Hatabu H, Ott PA, Armand PF, Hodi FS (2016) PD-1 inhibitor-related pneumonitis in advanced cancer patients: radiographic patterns and clinical course. Clin Cancer Res 22:6051\u20136060","journal-title":"Clin Cancer Res"},{"key":"917_CR21","doi-asserted-by":"publisher","first-page":"1700050","DOI":"10.1183\/13993003.00050-2017","volume":"50","author":"M Delaunay","year":"2017","unstructured":"Delaunay M, Cadranel J, Lusque A et al (2017) Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. Eur Respir J 50:1700050","journal-title":"Eur Respir J"},{"key":"917_CR22","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1200\/JCO.2016.68.2005","volume":"35","author":"J Naidoo","year":"2017","unstructured":"Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, Chaft JE, Segal NH, Callahan MK, Lesokhin AM, Rosenberg J, Voss MH, Rudin CM, Rizvi H, Hou X, Rodriguez K, Albano M, Gordon RA, Leduc C, Rekhtman N, Harris B, Menzies AM, Guminski AD, Carlino MS, Kong BY, Wolchok JD, Postow MA, Long GV, Hellmann MD (2017) Pneumonitis in patients treated with anti-programmed death-1\/programmed death ligand 1 therapy. J Clin Oncol 35:709\u2013717","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s10637-020-00969-4","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T00:00:00Z","timestamp":1593129600000}}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00917-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-020-00917-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-020-00917-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:45:57Z","timestamp":1678509957000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-020-00917-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,3]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["917"],"URL":"https:\/\/doi.org\/10.1007\/s10637-020-00917-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s10637-020-00969-4","asserted-by":"object"}]},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,3]]},"assertion":[{"value":"17 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2020","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Corrections are needed to the original version of this article. In Table 2, the \u201cOdds ratio\u201d of the variables \u201cLower lobe vs. Upper lobe\u201d and \u201c\u226526 vs. &lt;26\u201d should be 2.250 instead of 2250 and 2.250 instead of 2.25.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"H Inoue declares that he has no conflict of interest. A Ono received honoraria from AstraZeneca. T Kawabata declares that he has no conflict of interest. N mamesaya received honoraria from AstraZeneca. T Kawamura declares that he has no conflict of interest. H Kobayashi declares that he has no conflict of interest. S Omori received honoraria from AstraZeneca. K Wakuda received honoraria from AstraZeneca. H Kenmotsu received honoraria and research funding to our institution from AstraZeneca. T Naito declares that he has no conflict of interest. H Murakami received honoraria and research funding to our institution from AstraZeneca. K Yasui declares that he has no conflict of interest. H Ogawa declares that he has no conflict of interest. T Onoe declares that he has no conflict of interest. M Endo received honoraria from AstraZeneca. H Harada received honoraria from AstraZeneca. T Takahashi received honoraria and research funding to our institution from AstraZeneca.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional Review Board of Shizuoka Cancer Center (reference number: 30-J134\u201330\u20131-3) and with the 1964 Helsinki declaration and its later amendments or with comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"For this type of study, formal consent is not required.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}